Jasmina Ivanova

Pfizer (United States) — United States

Medicine · Health Sciences

21h-index1.7kcitations131works2.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Prostate Cancer Treatment and Research(34), Diabetes Management and Research(21), Diabetes Treatment and Management(14), Cancer, Lipids, and Metabolism(13), Diabetes Management and Education(12)

Publications131 total

Corticosteroid Use and Risk of Adverse Events in Metastatic Hormone‐Sensitive Prostate Cancer
The Prostate·2026Open Access
Impact of treatment suspension on health-related quality of life in the EMBARK trial: a post hoc analysis
EClinicalMedicine·2025· 1 citedOpen Access
How low do you need to go? Association between various prostate-specific antigen (PSA) response measures and clinical outcomes in metastatic castration-sensitive prostate cancer (mCSPC) in the Veteran Health Administration (VHA) data.
Journal of Clinical Oncology·2025· 1 cited
Cardiovascular (CV) event risk in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with enzalutamide (ENZA) or abiraterone acetate (AA) in the United States (US).
Journal of Clinical Oncology·2025· 1 cited
Corticosteroid (CS) use and risk of adverse events (AEs) in patients (pts) treated for metastatic hormone-sensitive prostate cancer (mHSPC).
Journal of Clinical Oncology·2025
Evaluating overall survival with abiraterone acetate compared to enzalutamide in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer: Real-world data from the Flatiron electronic health records database.
Journal of Clinical Oncology·2025
Plain language summary: how long do patients with metastatic castration-resistant prostate cancer (mCRPC) live when taking abiraterone or enzalutamide in the real world?
Future Oncology·2025· 1 citedOpen Access
Effects of Enzalutamide on the Sexual Activity of Patients with Biochemically Recurrent Prostate Cancer: A Post Hoc Analysis of Patient-reported Outcomes in the EMBARK Study
European Urology·2025· 8 citedOpen Access
Racial Differences in Survival and Healthcare Resource Utilization Among Medicaid-Insured Adults With Metastatic Prostate Cancer
Clinical Genitourinary Cancer·2024Open Access
P131 Real-world overall survival of enzalutamide versus abiraterone in metastatic castration-resistant prostate cancer: A targeted literature review
European Urology Open Science·2024· 1 citedOpen Access
Real-world outcomes following biochemical recurrence after definitive therapy with a short prostate-specific antigen doubling time: potential role of early secondary treatment
Prostate Cancer and Prostatic Diseases·2024· 5 citedOpen Access
EMBARK post hoc analysis of sexual activity (SA) patient-reported outcomes (PROs) in patients (pts) who were sexually active or interested in sex at baseline (BL).
Journal of Clinical Oncology·2024
EMBARK post hoc analysis of impact of treatment suspension (TxS) on health-related quality of life (HRQoL).
Journal of Clinical Oncology·2024· 1 cited
Real-world overall survival with abiraterone acetate versus enzalutamide in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer
Prostate Cancer and Prostatic Diseases·2024· 17 citedOpen Access
Treatment Patterns and Clinical Outcomes Among Patients With Metastatic Prostate Cancer Harboring Homologous Recombination Repair Mutations
Clinical Genitourinary Cancer·2024· 1 citedOpen Access
LONGITUDINAL CHANGES IN PATIENT-REPORTED OUTCOMES (PROs) IN PATIENTS WITH HIGH-RISK BIOCHEMICALLY RECURRENT (BCR) NONMETASTATIC CASTRATION-SENSITIVE PROSTATE CANCER (NMCSPC) FROM THE EMBARK STUDY
Urologic Oncology Seminars and Original Investigations·2024
What criteria do clinicians use to classify men as “high risk” among patients with biochemically recurrent nonmetastatic castration-sensitive prostate cancer?
Journal of Clinical Oncology·2024· 1 cited
Real-world treatment patterns for patients with high-risk biochemically recurrent nonmetastatic castration-sensitive prostate cancer.
Journal of Clinical Oncology·2024· 1 cited
EMBARK post hoc analysis of sexual activity (SA) patient-reported outcome (PRO) measures.
Journal of Clinical Oncology·2024· 1 cited
The Iconic Component of the Creolized Text of the Soviet Media as a Way of Implementing Ideological Narratives (Based on the Material of the Regional Newspaper of the 20s of the XX сentury of the Vladimir Province "Red Youth")
Art Logos – The Art of Word·2024
page 1 of 7Next →

Frequent Co-authors

Howard G. Birnbaum(27), Magaly Perez‐Nieves(9), Irene Hadjiyianni(9), Dachuang Cao(8), Stephen J. Freedland(6), Noam Y. Kirson(5), Gene Colice(4), Yohanne Kidolezi(4), Bhakti Arondekar(4), Tracy Waldman(4), Urvi Desai(4), Ralph Swindle(4), Rachael Sorg(4), Rachel Bergman(3), Vijay N. Joish(3), Todd Williamson(3), Matthew M. Hsieh(3), Alexander Niyazov(3), Mei Sheng Duh(3), Lawrence Fisher(3)